OBIO vs. TMCI, DCTH, CARL, NPCE, DRTS, RXST, TCMD, BWAY, SMTI, and SNWV
Should you be buying Orchestra BioMed stock or one of its competitors? The main competitors of Orchestra BioMed include Treace Medical Concepts (TMCI), Delcath Systems (DCTH), Carlsmed (CARL), NeuroPace (NPCE), Alpha Tau Medical (DRTS), RxSight (RXST), Tactile Systems Technology (TCMD), Brainsway (BWAY), Sanara MedTech (SMTI), and Sanuwave Health (SNWV). These companies are all part of the "medical equipment" industry.
Orchestra BioMed vs. Its Competitors
Orchestra BioMed (NASDAQ:OBIO) and Treace Medical Concepts (NASDAQ:TMCI) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and dividends.
53.2% of Orchestra BioMed shares are held by institutional investors. Comparatively, 84.1% of Treace Medical Concepts shares are held by institutional investors. 8.1% of Orchestra BioMed shares are held by insiders. Comparatively, 27.7% of Treace Medical Concepts shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Orchestra BioMed has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500. Comparatively, Treace Medical Concepts has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500.
Orchestra BioMed currently has a consensus price target of $13.50, suggesting a potential upside of 306.63%. Treace Medical Concepts has a consensus price target of $9.67, suggesting a potential upside of 50.10%. Given Orchestra BioMed's stronger consensus rating and higher possible upside, equities analysts clearly believe Orchestra BioMed is more favorable than Treace Medical Concepts.
In the previous week, Treace Medical Concepts had 1 more articles in the media than Orchestra BioMed. MarketBeat recorded 3 mentions for Treace Medical Concepts and 2 mentions for Orchestra BioMed. Treace Medical Concepts' average media sentiment score of 0.77 beat Orchestra BioMed's score of 0.67 indicating that Treace Medical Concepts is being referred to more favorably in the news media.
Treace Medical Concepts has higher revenue and earnings than Orchestra BioMed. Treace Medical Concepts is trading at a lower price-to-earnings ratio than Orchestra BioMed, indicating that it is currently the more affordable of the two stocks.
Treace Medical Concepts has a net margin of -23.01% compared to Orchestra BioMed's net margin of -2,367.49%. Treace Medical Concepts' return on equity of -46.76% beat Orchestra BioMed's return on equity.
Summary
Treace Medical Concepts beats Orchestra BioMed on 11 of the 17 factors compared between the two stocks.
Get Orchestra BioMed News Delivered to You Automatically
Sign up to receive the latest news and ratings for OBIO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding OBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Orchestra BioMed Competitors List
Related Companies and Tools
This page (NASDAQ:OBIO) was last updated on 10/17/2025 by MarketBeat.com Staff
